Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2022

The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL) therapy market. Key therapies expected to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), targeted agents Polivy (Roche), Monjuvi / Minjuvi (MorphoSys / Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), Zynlonta (ADC Therapeutics), as well as the approval of first-in-class bispecific antibody, Lunsumio (Roche). In addition, combinations incorporating Imbruvica (Janssen / AbbVie), Calquence (AstraZeneca), and Venclexta / Venclyxto (AbbVie / Roche) will enter the CLL market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the other bispecific antibodies glofitamab (Roche) and epcoritamab (Genmab / AbbVie) and the noncovalent BTK inhibitor pirtobrutinib (Loxo Oncology / Eli Lilly) will further fragment the DLBCL, FL, and CLL / SLL patient settings, creating intense competition.

Questions Answered

• What is the size of clinically and commercially relevant drug-treatable NHL / CLL populations, and how will drug-treatment rates change over the 2021-2031 forecast period, by geography?
• What is the expected market impact of recent drug approvals and label expansions on the various NHL / CLL patient populations?
• Which emerging therapies are the most promising in NHL / CLL, and what patient populations will they target? What will be their impact on the NHL / CLL market?
• What factors are driving growth in the NHL / CLL market? Which drug class will dominate the treatment of NHL / CLL?

Content Highlights

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.

Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia / small lymphocytic leukemia) and line of therapy.

Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL / SLL, DLBCL, and MCL.

Emerging therapies: Phase III / PR: 11 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.